FDA Grants Third Year of Orphan Products Funding for QTORIN Rapamycin in Microcystic Lymphatic Malformations
核心洞察
Palvella Therapeutics (搜索) received a third year of grant funding from the FDA Office of Orphan Products Development for the Phase 3 SELVA trial and its open-label extension.
The Phase 3 SELVA trial met its primary endpoint, pre-specified key secondary endpoint and all four secondary efficacy endpoints, with all six achieving p<0.001.
Palvella completed its rolling NDA submission for QTORIN 3.9% rapamycin anhydrous gel in August 2026 and is preparing for a potential U.S. launch in the first half of 2027.
Palvella Therapeutics (搜索) has received a third year of grant funding from the FDA Office of Orphan Products Development to support the Phase 3 SELVA trial and the ongoing open-label extension study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin (搜索)) for the treatment of microcystic lymphatic malformations (搜索). The award followed the FDA's review of the company's annual performance progress report, which included results from the Phase 3 SELVA trial.
The Wayne, Pennsylvania-based company completed submission of its New Drug Application for QTORIN rapamycin (搜索) in August 2026, filed on a rolling basis. Palvella said it is advancing commercial readiness for a potential U.S. launch in the first half of 2027, contingent on regulatory approval.
SELVA Results and Regulatory Designations
In February 2026, Palvella reported positive topline results from the Phase 3 SELVA trial. The trial met its primary endpoint, its pre-specified key secondary endpoint and all four secondary efficacy endpoints, with all six efficacy endpoints achieving statistical significance (all p<0.001).
QTORIN rapamycin (搜索) has received Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA. The SELVA trial was one of only seven new clinical trials selected for funding from 51 applications received by the FDA Orphan Products Grants Program in fiscal year 2024, and the only Phase 3 trial awarded a grant that year. Grant applications are independently reviewed and scored for scientific and technical merit by rare disease and regulatory experts and may involve consultation with the relevant FDA review division. Since its inception, the program has funded clinical trials that have facilitated the approval of more than 85 medical products for rare diseases.
"We are grateful for the FDA's continued support of the QTORIN rapamycin (搜索) program, including funding through the Orphan Products Grants Program, Breakthrough Therapy, Fast Track, and Orphan Drug designations, and the opportunity to submit our NDA on a rolling basis," said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. "Following positive Phase 3 SELVA results and completion of our NDA submission, we are advancing commercial readiness for a potential U.S. launch in the first half of 2027, if approved."
Unmet Need in a Rare Vascular Anomaly
Microcystic lymphatic malformations (搜索) are a rare vascular anomaly affecting an estimated more than 30,000 pediatric and adult patients in the United States. There are currently no FDA-approved therapies for the condition, which Palvella describes as serious and lifelong. Kaupinen said QTORIN rapamycin (搜索) has the potential to become the first FDA-approved therapy for microcystic LMs and to establish a new standard of care for these patients.
Broader QTORIN Platform
QTORIN rapamycin (搜索) is being developed as a topical therapy and is also under investigation for cutaneous venous malformations (搜索) and clinically significant angiokeratomas (搜索). Palvella's second product candidate, QTORIN pitavastatin (搜索), is in development for disseminated superficial actinic porokeratosis (搜索).
Both QTORIN rapamycin (搜索) and QTORIN pitavastatin (搜索) are for investigational use only and neither has been approved by the FDA or any other regulatory agency for any indication.